By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Biotechnology. According to news reporting originating from Udine, Italy, by NewsRx correspondents, research stated, "Cisplatin-based chemotherapy has been shown to improve survival in cervical cancer; however, treatment is associated with tumor resistance and significant toxicity. Lipoplatin is a new liposomal formulation of cisplatin, developed to reduce cisplatin toxicity, to improve drug accumulation at tumor sites and to overcome drug resistance."
Our news editors obtained a quote from the research from the University of Udine, "The aim of this study is to analyze the antitumoral activity of lipoplatin against cisplatin-resistant cervical cancer cells and to investigate its mechanism of action. The activity and mechanism of action of lipoplatin were studied in the ME-180 cervical cancer cell line and its cisplatin-resistant clone R-ME-180 and HeLa cells using cell proliferation assays, flow cytometry, ELISA assay, cell migration, spheroids and tumor xenograft. We demonstrated that lipoplatin exhibited a potent antitumoral activity on HeLa, ME-180 cells and its cisplatin-resistant clone R-ME-180. Lipoplatin inhibited cell proliferation in a dose-dependent manner and was more active than the reference drug cisplatin in R-ME-180 cells and induced apoptosis, as evaluated by Annexin-V staining and DNA fragmentation, caspases 9 and 3. activation, Bcl-2, and Bcl-xL down-regulation, but Bax up-regulation inhibited thioredoxin reductase (TrxR) enzymatic activity and increased reactive oxygen species (ROS) accumulation; reduced EGFR expression and inhibited both migration and invasion. R-ME-180, but not ME-180 cells, generated three-dimensional (3D)-multicellular spheroids expressing the cancer stem cell marker ALDH. The ability of R-ME-180 cells to form spheroids in vitro and tumors in nude mice was also remarkably decreased by lipoplatin."
According to the news editors, the research concluded: "Overall, our results suggest that lipoplatin has potential for the treatment of cisplatin-resistant cervical cancer."
For more information on this research see: Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer. Gynecologic Oncology, 2013;131(3):744-752. Gynecologic Oncology can be contacted at: Academic Press Inc Elsevier Science, 525 B St, Ste 1900, San Diego, CA 92101-4495, USA. (Elsevier - www.elsevier.com; Gynecologic Oncology - www.elsevier.com/wps/product/cws_home/622840)
The news editors report that additional information may be obtained by contacting N. Casagrande, University of Udine, MATI Micrograv Ageing Training Immobil Excellence, I-33100 Udine, Italy. Additional authors for this research include M. De Paoli, M. Celegato, C. Borghese, M. Mongiat, A. Colombatti and D. Aldinucci (see also Biotechnology).
Keywords for this news article include: Antineoplastics, Biotechnology, Pharmaceuticals, Udine, Italy, Drugs, Europe, Cancer, Oncology, Cisplatin, Liposomes, Treatment, Chemotherapy, Alkylating Agents, Chlorine Compounds, Nitrogen Compounds, Platinum Compounds
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC